-
公开(公告)号：US10246489B2
公开(公告)日：2019-04-02
申请号：US15446253
申请日：2017-03-01
申请人： Jeffrey D. Rimer , Pankaj Karande
发明人： Jeffrey D. Rimer , Pankaj Karande
摘要： In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity.
-
公开(公告)号：US09617306B2
公开(公告)日：2017-04-11
申请号：US14326908
申请日：2014-07-09
申请人： Jeffrey D. Rimer , Pankaj Karande
发明人： Jeffrey D. Rimer , Pankaj Karande
CPC分类号： C07K7/08 , A61K38/00 , G01N33/53 , G01N33/6893 , G01N2500/04 , G01N2500/20 , G01N2800/345
摘要： In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity.
-
3.发明申请Peptide Inhibitors of Calcium Oxalate Monohydrate Crystallization and Uses Thereof 有权一氧化钙一水合物结晶的肽抑制剂及其用途公开(公告)号：US20150099704A1
公开(公告)日：2015-04-09
申请号：US14326908
申请日：2014-07-09
申请人： Jeffrey D. Rimer , Pankaj Karande
发明人： Jeffrey D. Rimer , Pankaj Karande
CPC分类号： C07K7/08 , A61K38/00 , G01N33/53 , G01N33/6893 , G01N2500/04 , G01N2500/20 , G01N2800/345
摘要： In an embodiment, the present disclosure pertains to a composition for inhibiting calcium oxalate monohydrate crystal growth comprising at least one isolated polypeptide comprising a plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal; and a plurality of amino acids spacers, wherein the amino acid spacers are arranged in varying sequences between the plurality of amino acids that bind the surface of the calcium oxalate monohydrate crystal. In some embodiments, the present disclosure related to a method of controlling calcium oxalate monohydrate crystal growth in a subject in need thereof comprising administering to the subject therapeutically effective amount of the calcium oxalate monohydrate inhibiting polypeptide. In some embodiments, the present disclosure relates to a method of identifying calcium oxalate monohydrate inhibiting peptides. Such a method may comprise designing a peptide library of potential calcium oxalate inhibiting peptides; screening the peptide library for high efficacy inhibitor peptides for inhibition of calcium oxalate monohydrate crystallization; and conducting molecular characterization of the high efficacy inhibitor to determine specificity.
摘要翻译： 在一个实施方案中，本公开涉及用于抑制草酸钙一水合物晶体生长的组合物，其包含至少一种分离的多肽，其包含结合草酸钙一水合物晶体的表面的多个氨基酸; 和多个氨基酸间隔物，其中氨基酸间隔物以不同的顺序排列在结合草酸钙一水合物晶体的表面的多个氨基酸之间。 在一些实施方案中，本公开涉及在有需要的受试者中控制草酸钙一水合物晶体生长的方法，其包括向所述受试者施用治疗有效量的草酸钙一水合物抑制多肽。 在一些实施方案中，本公开涉及鉴定草酸钙一水合物抑制肽的方法。 这种方法可以包括设计潜在的草酸钙抑制肽的肽文库; 筛选用于抑制草酸钙一水合物结晶的高效抑制剂肽的肽文库; 并进行高效抑制剂的分子表征以确定特异性。
-
4.发明申请ORGANIC ACIDS AS GROWTH INHIBITORS OF PATHOLOGICAL CALCIFICATION AND USES THEREOF 审中-公开有机酸作为生长抑制剂的病理学计算及其用途公开(公告)号：US20150216825A1
公开(公告)日：2015-08-06
申请号：US14616035
申请日：2015-02-06
申请人： Jeffrey D. Rimer , John Asplin
发明人： Jeffrey D. Rimer , John Asplin
IPC分类号： A61K31/194
CPC分类号： A61K31/194
摘要： In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium oxalate crystal growth. In an embodiment of the present disclosure, there is provided a composition for inhibiting calcium phosphate crystal growth. In some embodiments, such a composition comprises at least one citrate derivative of an organic acid and at least one pharmaceutically acceptable carrier. In another embodiment, the present disclosure relates to a method of controlling calcium oxalate crystal growth in a subject in need thereof. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
摘要翻译： 在本公开的一个实施方案中，提供了用于抑制草酸钙晶体生长的组合物。 在本公开的一个实施方案中，提供了一种抑制磷酸钙晶体生长的组合物。 在一些实施方案中，这样的组合物包含至少一种有机酸的柠檬酸盐衍生物和至少一种药学上可接受的载体。 在另一个实施方案中，本公开涉及在有需要的受试者中控制草酸钙晶体生长的方法。 这种方法包括向受试者施用有效量的上述组合物。 在另一个实施方案中，本公开涉及治疗肾结石病症的方法。 这种方法包括向有需要的受试者施用治疗有效量的上述组合物。 在另一个实施方案中，本公开涉及治疗草酸钙石病的方法。 在一个实施方案中，该方法包括向有需要的受试者施用治疗有效量的上述组合物。
-
5.发明申请ZEOLITE COMPOSITIONS AND METHODS FOR TAILORING ZEOLITE CRYSTAL HABITS WITH GROWTH MODIFIERS 审中-公开沸石组合物和使用生长改性剂调配沸石晶体的方法公开(公告)号：US20120202006A1
公开(公告)日：2012-08-09
申请号：US13366206
申请日：2012-02-03
申请人： Jeffrey D. Rimer
发明人： Jeffrey D. Rimer
CPC分类号： C01B39/40 , C01B37/02 , C01B37/08 , C01B39/265 , C01B39/32 , C01B39/445 , C01B39/54 , Y10T428/24273
摘要： Embodiments of the invention generally provide compositions of crystalline zeolite materials with tailored crystal habits and the methods for forming such crystalline zeolite materials. The methods for forming the crystalline zeolite materials include binding one or more zeolite growth modifiers (ZGMs) to the surface of a zeolite crystal, which results in the modification of crystal growth rates along different crystallographic directions, leading to the formation of zeolites having a tailored crystal habit. The improved properties enabled by the tailored crystal habit include a minimized crystal thickness, a shortened internal diffusion pathlength, and a greater step density as compared to a zeolite having the native crystal habit prepared by traditional processes. The tailored crystal habit provides the crystalline zeolite materials with an aspect ratio of about 4 or greater and crystal surfaces having a step density of about 25 steps/μm2 or greater.
摘要翻译： 本发明的实施方案通常提供具有定制的晶体习惯的结晶沸石材料的组合物和形成这种结晶沸石材料的方法。 形成结晶沸石材料的方法包括将一种或多种沸石生长改性剂（ZGM）结合到沸石晶体的表面，这导致沿着不同的晶体方向改变晶体生长速率，导致形成具有定制的沸石 水晶习惯 与通过传统方法制备的具有天然结晶习性的沸石相比，通过定制的晶体习性实现的改进的性质包括最小化的晶体厚度，缩短的内部扩散路径长度和更大的阶梯密度。 定制的晶体习性提供了具有约4或更大的纵横比的结晶沸石材料和具有约25步/μm2或更大的阶梯密度的晶体表面。
-
6.发明申请ORGANIC ACIDS AS AGENTS TO DISSOLVE CALCIUM MINERALS IN PATHOLOGICAL CALCIFICATION AND USES THEREOF 审中-公开有机酸作为病原学计算中钙钙矿物的代理及其用途公开(公告)号：US20150297545A1
公开(公告)日：2015-10-22
申请号：US14696863
申请日：2015-04-27
申请人： Jeffrey D. Rimer , Jihae Chung , John Asplin
发明人： Jeffrey D. Rimer , Jihae Chung , John Asplin
IPC分类号： A61K31/194 , C07C59/245 , A61K45/06
CPC分类号： A61K31/194 , A61K45/06 , C07C59/245
摘要： In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
摘要翻译： 在本公开的一个实施方案中，提供了一种用于溶解草酸钙晶体从而抑制/防止晶体进一步生长的组合物。 在一些实施方案中，这种组合物包含至少一种羟基柠檬酸的立体异构体，有机酸柠檬酸盐的衍生物。 这种方法包括向受试者施用有效量的上述组合物。 在另一个实施方案中，本公开涉及治疗肾结石病症的方法。 这种方法包括向有需要的受试者施用治疗有效量的上述组合物。 在另一个实施方案中，本公开涉及治疗草酸钙石病的方法。 在一个实施方案中，该方法包括向有需要的受试者施用治疗有效量的上述组合物。
-
7.发明申请公开(公告)号：US20110177173A1
公开(公告)日：2011-07-21
申请号：US12953096
申请日：2010-11-23
申请人： Michael D. Ward , Jeffrey D. Rimer
发明人： Michael D. Ward , Jeffrey D. Rimer
CPC分类号： A61K31/223 , A61K31/10 , A61K31/105 , A61K31/145 , A61K45/06 , Y10S514/891
摘要： A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. R1a—O-(-A-L-)m-A-O—R1b I, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
摘要翻译： 公开了使用式I化合物预防或抑制L-胱氨酸结晶的方法。 R1a-O - （ - A-L-）m-A-O-R1b I，其中A，L，R1a，R1b和m如本文所述。 这些化合物可以制备成药物组合物，并且可以用于预防和治疗与L-胱氨酸结晶有因果关系的病症，例如包括（但不限于）肾结石。
-
8.发明授权公开(公告)号：US10285961B2
公开(公告)日：2019-05-14
申请号：US14696863
申请日：2015-04-27
申请人： Jeffrey D. Rimer , Jihae Chung , John Asplin
发明人： Jeffrey D. Rimer , Jihae Chung , John Asplin
IPC分类号： A61K31/194 , A61K45/06 , C07C59/245
摘要： In an embodiment of the present disclosure, there is provided a composition for dissolving calcium oxalate crystals thereby inhibiting/preventing further growth of crystals. In some embodiments, such a composition comprises at least one stereoisomer of hydroxycitrate, a derivative of the organic acid citrate. Such a method comprises administering to the subject an effective amount of the aforementioned composition. In another embodiment, the present disclosure pertains to a method of treating kidney stone disorder. Such a method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition. In yet another embodiment, the present disclosure relates to a method of treating calcium oxalate stone disease. In an embodiment, the method comprises administering to a subject in need thereof a therapeutically effective amount of the aforementioned composition.
-
公开(公告)号：US09714174B2
公开(公告)日：2017-07-25
申请号：US13946919
申请日：2013-07-19
CPC分类号： C01B39/02 , C01B39/46 , C01B39/50 , C01B39/52 , C01P2004/20 , C01P2004/54
摘要： Methods of controlling crystal polymorphism in organic-free synthesis of Na-Zeolites and the zeolite crystals formed using those methods are provided. The methods disclosed herein create certain types of zeolite crystals more efficiently than other previously known methods. The methods also create certain types of zeolite crystals in a form and concentration not previously disclosed. The methods disclosed herein generally comprise using solutions with varying ratios of silicon (Si), aluminum (Al), hydroxide (OH), and water. Some implementations of the invention disclosed include efficient methods of producing nearly pure cancrinite (CAN), methods of obtaining sodalite in solutions with a high Si/Al ratio, and a method of forming thin, platelet-like ANA crystals with a width of less than about 1 μm and a length of at least about 3 μm.
-
公开(公告)号：US08450089B2
公开(公告)日：2013-05-28
申请号：US12953096
申请日：2010-11-23
申请人： Michael D. Ward , Jeffrey D. Rimer
发明人： Michael D. Ward , Jeffrey D. Rimer
IPC分类号： A61K38/05 , A61K31/21 , A61K31/225 , A61K31/22 , C12P13/12
CPC分类号： A61K31/223 , A61K31/10 , A61K31/105 , A61K31/145 , A61K45/06 , Y10S514/891
摘要： A method of preventing or inhibiting L-cystine crystallization using the compounds of formula I is disclosed. R1a—O-(-A-L-)m-A-O—R1b I, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
摘要翻译： 公开了使用式I化合物预防或抑制L-胱氨酸结晶的方法。 R1a-O - （ - A-L-）m-A-O-R1b1，其中A，L，R1a，R1b和m如本文所述。 这些化合物可以制备成药物组合物，并且可以用于预防和治疗与L-胱氨酸结晶有因果关系的病症，例如包括（但不限于）肾结石。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.02 秒)